Diallyl Sulfide: Potential Use in Novel Therapeutic Interventions in Alcohol, Drugs, and Disease Mediated Cellular Toxicity by Targeting Cytochrome P450 2E1.
Diallyl sulfide (DAS) and other organosulfur compounds are chief constituents of garlic. These compounds have many health benefits, as they are very efficient in detoxifying natural agents. Therefore, these compounds may be useful for prevention/treatment of cancers. However, DAS has shown appreciable allergic reactions and toxicity, as they can also affect normal cells. Thus their use as in the prevention and treatment of cancer is limited. DAS is a selective inhibitor of cytochrome P450 2E1 (CYP2E1), which is known to metabolize many xenobiotics including alcohol and analgesic drugs in the liver. CYP2E1-mediated alcohol/drug metabolism produce reactive oxygen species and reactive metabolites, which damage DNA, protein, and lipid membranes, subsequently causing liver damage. Several groups have shown that DAS is not only capable of inhibiting alcohol- and drug-mediated cellular toxicities, but also HIV protein- and diabetes-mediated toxicities by selectively inhibiting CYP2E1 in various cell types. However, due to known DAS toxicities, its use as a treatment modality for alcohol/drug- and HIV/diabetes-mediated toxicity have only limited clinical relevance. Therefore, effort is being made to generate DAS analogs, which are potent and selective inhibitor of CYP2E1 and poor substrate of CYP2E1. This review summarizes current advances in the field of DAS, its anticancer properties, role as a CYP2E1 inhibitor, preventing agent of cellular toxicities from alcohol, analgesic drugs, xenobiotics, as well as, from diseases like HIV and diabetes. Finally, this review also provides insights toward developing novel DAS analogues for chemical intervention of many disease conditions by targeting CYP2E1 enzyme.
P S S
PS
Rao
Narasimha M
NM
Midde
Duane D
DD
Miller
Subhash
S
Chauhan
Anil
A
Kumar
College of Pharmacy, University of Tennessee Health Science Center, 881 Madison Ave, Rm 456, Memphis, TN 38163, USA. ksantosh@uthsc.edu.
Santosh
S
Kumar
D000498:Allyl Compounds / Q000494:pharmacology / Q000627:therapeutic use; D000700:Analgesics / Q000633:toxicity; D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use; D019392:Cytochrome P-450 CYP2E1 / Q000378:metabolism*; D019610:Cytoprotection; D000431:Ethanol / Q000633:toxicity; D006801:Humans; D020011:Protective Agents / Q000494:pharmacology / Q000627:therapeutic use; D013440:Sulfides / Q000494:pharmacology / Q000627:therapeutic use; D015262:Xenobiotics / Q000633:toxicity
D000498:Allyl Compounds; D000700:Analgesics; D000970:Antineoplastic Agents; D020011:Protective Agents; D013440:Sulfides; D015262:Xenobiotics; D000431:Ethanol; C038491:allyl sulfide; D019392:Cytochrome P-450 CYP2E1